FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, and aims at treating neurodegenerative disease. Selenate and a pharmaceutically acceptable salt thereof are applied in the methods and compositions.
EFFECT: group of inventions enables reducing the onset of neurodegenerative diseases due to increased activity of PP2A protein phosphatase, reducing phosphorylation of tau protein and GSK3J3 activity inhibition.
22 cl, 4 tbl, 17 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING NEUROLOGICAL DISORDERS | 2008 |
|
RU2492137C2 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2450000C2 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2429237C2 |
| SULPHATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOLE-2-AMINE, PREPARATION THEREOF AND USE OF SAME | 2013 |
|
RU2655454C2 |
| METHOD FOR PREVENTING AND TREATING NEURODEGENERATIVE PATHOLOGY AND VASCULAR DEMENTIA | 2014 |
|
RU2587617C1 |
| PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASE | 2012 |
|
RU2618412C2 |
| THERAPEUTIC FOR THE TREATMENT OF LEWY BODY DISEASE CONTAINING PYRAZOLOQUINOLINE DERIVATIVE | 2018 |
|
RU2802212C2 |
| ALPHA-SYNUCLEIN MODULATORS | 2018 |
|
RU2797677C2 |
| AGENT FOR PREVENTING AND TREATING NEURODEGENERATIVE PATHOLOGY AND VASCULAR DEMENTIA (VERSIONS) | 2014 |
|
RU2582962C1 |
| PENTACYCLIC COMPOUND | 2018 |
|
RU2754557C1 |
